Valuation: Grace Therapeutics, Inc.

Market Cap 57.47M 40.52M 35.54M 32.81M 30.32M 3.88B 58.62M 394M 153M 1.9B 152M 149M 6.59B P/E 2027 *
-4.79x
P/E 2028 * -4.56x
Enterprise Value 57.47M 40.52M 35.54M 32.81M 30.32M 3.88B 58.62M 394M 153M 1.9B 152M 149M 6.59B EV / Sales 2027 *
-
EV / Sales 2028 * 7.34x
Free-Float
74.27%
Yield 2027 *
-
Yield 2028 * -
1 day-0.80%
1 week+11.16%
Current month+9.69%
1 month+8.26%
3 months-30.25%
6 months-34.47%
Current year-28.03%
1 week 2.35
Extreme 2.35
2.58
1 month 2.08
Extreme 2.0782
2.58
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
27.36
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 03/04/2023
Director of Finance/CFO 54 04/01/2024
Chief Tech/Sci/R&D Officer 64 07/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 03/04/2023
Director/Board Member 59 09/10/2023
Date Insider Type Main position Quantity % Market Cap.
01-11Option

Director

10,000 0.0646%
01-11Option

Director

10,000 0.0646%
01-11Option

Chairman

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%+11.16%-18.09%-20.19% 40.52M
-1.53%+0.78%+72.33%+129.70% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+3.27%+8.91%+21.21%+486.76% 25.26B
-0.81%-0.42%-16.24%-12.47% 23.65B
+3.53%+2.96%+42.55%-2.84% 18.69B
-0.24%+5.11%+38.76%-26.41% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-1.79%+0.60%+34.48% - 14.26B
-1.70%+3.98%+28.96%+190.57% 14.1B
Average -0.03%+4.73%+49.19%+134.36% 23.94B
Weighted average by Cap. -0.40%+2.20%+57.97%+144.47%

Financials

2027 *2028 *
Net sales - 7.83M 5.52M 4.84M 4.47M 4.13M 529M 7.99M 53.77M 20.89M 259M 20.74M 20.29M 898M
Net income -12.76M -9M -7.89M -7.28M -6.73M -861M -13.01M -87.57M -34.03M -422M -33.78M -33.04M -1.46B -20.46M -14.43M -12.66M -11.68M -10.8M -1.38B -20.87M -140M -54.57M -676M -54.18M -53M -2.35B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
08/07/26 US$2.490 -0.80% 109,517
07/07/26 US$2.510 -0.79% 165,799
06/07/26 US$2.530 +6.75% 273,822
02/07/26 US$2.370 +5.80% 268,970
01/07/26 US$2.240 -1.32% 251,044
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.532CAD
Average target price
8.447CAD
Spread / Average Target
+139.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock